Total Payments
$89,958
2023 Payments
$250.74
Companies
11
Transactions
82
Medicare Patients
403
Medicare Billing
$35,925
Payment Breakdown by Category
Consulting$63,067 (70.1%)
Research$13,793 (15.3%)
Other$6,748 (7.5%)
Travel$4,478 (5.0%)
Food & Beverage$1,872 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $63,067 | 17 | 70.1% |
| Unspecified | $13,793 | 11 | 15.3% |
| Travel and Lodging | $4,478 | 19 | 5.0% |
| Honoraria | $4,375 | 2 | 4.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,373 | 2 | 2.6% |
| Food and Beverage | $1,872 | 31 | 2.1% |
Payments by Type
General
$76,165
71 transactions
Research
$13,793
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $25,747 | 9 | $0 (2021) |
| GENZYME CORPORATION | $18,147 | 10 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $14,806 | 21 | $0 (2021) |
| Merck Sharp & Dohme LLC | $14,542 | 23 | $0 (2022) |
| ARRAY BIOPHARMA INC | $6,600 | 4 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $3,785 | 8 | $0 (2023) |
| Genentech USA, Inc. | $1,980 | 1 | $0 (2021) |
| Eisai Inc. | $1,875 | 1 | $0 (2021) |
| F. Hoffmann-La Roche AG | $1,623 | 2 | $0 (2022) |
| Eli Lilly and Company | $623.20 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $250.74 | 3 | Regeneron Pharmaceuticals, Inc. ($250.74) |
| 2022 | $12,251 | 16 | Merck Sharp & Dohme LLC ($8,439) |
| 2021 | $16,181 | 8 | Merck Sharp & Dohme Corporation ($3,000) |
| 2020 | $9,853 | 4 | GENZYME CORPORATION ($4,315) |
| 2019 | $32,898 | 36 | GENZYME CORPORATION ($13,832) |
| 2018 | $17,603 | 12 | NOVARTIS PHARMACEUTICALS CORPORATION ($10,779) |
| 2017 | $922.04 | 3 | Eli Lilly and Company ($623.20) |
All Payment Transactions
82 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/13/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $85.24 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 01/12/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $85.24 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 01/12/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $80.26 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 12/05/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $21.35 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 12/02/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $93.99 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 12/01/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $229.76 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 09/09/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $241.91 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 06/29/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 06/29/2022 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 06/23/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $310.00 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $163.75 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $64.28 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $54.91 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $51.46 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $590.62 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $196.66 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $146.85 | General |
| Category: ONCOLOGY | ||||||
| 03/31/2022 | F. Hoffmann-La Roche AG | Erivedge (Biological) | — | In-kind items and services | $1,350.00 | Research |
| Study: A PROSPECTIVE OBSERVATIONAL STUDY OF TREATMENT PATTERNS AND EFFECTIVENESS AND SAFETY OUTCOMES IN ADVANCED BASAL CELL CARCINOMA AND BASAL CELL CARCINOMA NEVUS SYNDROME PATIENTS • Category: BioOncology | ||||||
| 01/14/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Honoraria | Cash or cash equivalent | $1,875.00 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $1,691.25 | General |
| Category: Oncology | ||||||
| 11/05/2021 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Consulting Fee | Cash or cash equivalent | $2,187.50 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 08/13/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $2,947.50 | General |
| Category: ONCOLOGY | ||||||
| 06/30/2021 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: Oncology | ||||||
| 06/25/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $10,779 | 1 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF TREATMENT PATTERNS AND EFFECTIVENESS AND SAFETY OUTCOMES IN ADVANCED BASAL CELL CARCINOMA AND BASAL CELL CARCINOMA NEVUS SYNDROME PATIENTS | F. Hoffmann-La Roche AG | $1,350 | 1 |
| REGN3767 CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $837.75 | 7 |
| A PHASE 1A-1B TRIAL INVESTIGATING THE CSF-1R INHIBITOR LY3022855 IN COMBINATION WITH DURVALUMAB -MEDI4736- OR TREMELIMUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | Eli Lilly and Company | $623.20 | 1 |
| A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS | TESARO, Inc. | $203.76 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 64 | 78 | $32,862 | $5,143 |
| 2021 | 5 | 152 | 199 | $74,108 | $14,622 |
| 2020 | 7 | 187 | 246 | $83,945 | $16,160 |
Total Patients
403
Total Services
523
Medicare Billing
$35,925
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 21 | $12,159 | $2,184 | 18.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 26 | 33 | $13,695 | $1,926 | 14.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 24 | $7,008 | $1,033 | 14.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 34 | 45 | $23,591 | $4,990 | 21.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 48 | 56 | $21,290 | $3,750 | 17.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 17 | 42 | $9,742 | $2,213 | 22.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 36 | 39 | $10,228 | $1,908 | 18.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $9,257 | $1,761 | 19.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 44 | 78 | $17,952 | $4,547 | 25.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 31 | 41 | $19,485 | $3,334 | 17.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 39 | 47 | $16,765 | $2,463 | 14.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 37 | 43 | $10,596 | $1,740 | 16.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 12 | 12 | $8,127 | $1,671 | 20.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 13 | 13 | $7,069 | $1,381 | 19.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 12 | $3,951 | $1,024 | 25.9% |
About Dr. Ragini Kudchadkar, MD
Dr. Ragini Kudchadkar, MD is a Medical Oncology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1982750667.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ragini Kudchadkar, MD has received a total of $89,958 in payments from pharmaceutical and medical device companies, with $250.74 received in 2023. These payments were reported across 82 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($63,067).
As a Medicare-enrolled provider, Kudchadkar has provided services to 403 Medicare beneficiaries, totaling 523 services with total Medicare billing of $35,925. Data is available for 3 years (2020–2022), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Atlanta, GA
- Active Since 01/26/2007
- Last Updated 03/03/2016
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1982750667
Products in Payments
- MEKINIST (Drug) $14,969
- LIBTAYO (Drug) $13,832
- TAFINLAR (Drug) $10,779
- BRAFTOVI (Drug) $4,375
- Erivedge (Biological) $3,603
- OPDIVO (Biological) $3,360
- KEYTRUDA (Biological) $3,182
- LIBTAYO (Biological) $2,948
- Braftovi (Drug) $2,225
- Lenvima (Drug) $1,875
- ZEJULA (Drug) $26.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Atlanta
Dr. Suresh Ramalingam, Md, MD
Medical Oncology — Payments: $180,916
Medical Oncology $180,916
Nabil Saba, M.d, M.D
Medical Oncology — Payments: $171,657
Medical Oncology $171,657
Eyal Meiri, M.d, M.D
Medical Oncology — Payments: $38,153
Medical Oncology $38,153
Erin Dunbar, Md, MD
Medical Oncology — Payments: $34,123
Medical Oncology $34,123
Amelia Langston, M.d, M.D
Medical Oncology — Payments: $31,176
Medical Oncology $31,176
Ruth Sacks, M.d, M.D
Medical Oncology — Payments: $18,254
Medical Oncology $18,254